Stocks · News reference

FDA Lifts Clinical Hold Form Filana Therapeutics' Investigational New Drug Application To Initiate Planned Phase 2a Trial In Participants With Tuberous Sclerosis Complex-Related Epilepsy

Sep 22, 2026, 12:06 PMBenzinga Newsdesk

Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing simufilam for the treatment of Tuberous Sclerosis Complex

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

FLNA

Source: benzinga
Observed: Sep 22, 2026, 12:06 PM
Checked: Sep 22, 2026, 12:06 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

Globenewswire IncOct 9, 2026, 12:00 PMNa
Filana Therapeutics to Participate in the 2026 Maxim Growth Summit
Filana Therapeutics (NASDAQ: FLNA), a biotechnology company developing therapies for TSC-related epilepsy, announced that its management team will participate in the 2026 Maxim Growth Summit scheduled for October 12-14, 2026 in New York. The company will engage in one-on-one meetings at the event.
FLNA
BenzingaOct 1, 2026, 2:25 PMBenzinga Newsdesk
Filana Therapeutics shares are trading higher after a Form 4 filing showed its President & CEO bought 306,813 shares at an average price of $0.91 each.
FLNA
BenzingaSep 22, 2026, 4:47 PMVandana Singh
Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research Forward
The FDA lifted a clinical hold on Filana Therapeutics' IND application, allowing a Phase 2a trial for a TSC-related epilepsy treatment.
FLNA
BenzingaSep 22, 2026, 12:55 PMBenzinga Newsdesk
Filana Therapeutics shares are trading higher after the company announced that the FDA lifted the clinical hold on its investigational new drug application, enabling Filana to initiate a planned Phase 2a proof-of-concept study in patients aged 12 to 55 with TSC-related epilepsy.
FLNA

FDA Lifts Clinical Hold Form Filana Therapeutics' Investigational New Drug Application To Initiate Planned Phase 2a Trial In Participants With Tuberous Sclerosis Complex-Related Epilepsy

Connected Markets

Related Headlines

Filana Therapeutics to Participate in the 2026 Maxim Growth Summit

Filana Therapeutics shares are trading higher after a Form 4 filing showed its President & CEO bought 306,813 shares at an average price of $0.91 each.

Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research Forward

Filana Therapeutics shares are trading higher after the company announced that the FDA lifted the clinical hold on its investigational new drug application, enabling Filana to initiate a planned Phase 2a proof-of-concept study in patients aged 12 to 55 with TSC-related epilepsy.